These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30772001)

  • 1. Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study.
    Montastruc F; Renoux C; Hudson M; Dell'Aniello S; Simon TA; Suissa S
    Semin Arthritis Rheum; 2019 Jun; 48(6):1053-1058. PubMed ID: 30772001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study.
    Montastruc F; Renoux C; Dell'Aniello S; Simon TA; Azoulay L; Hudson M; Suissa S
    Rheumatology (Oxford); 2019 Apr; 58(4):683-691. PubMed ID: 30535094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
    Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
    Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.
    Chen SK; Liao KP; Liu J; Kim SC
    Arthritis Care Res (Hoboken); 2020 Jan; 72(1):9-17. PubMed ID: 30570833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
    Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
    Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
    Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
    Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study.
    Suissa S; Hudson M; Dell'Aniello S; Shen S; Simon TA; Ernst P
    Semin Arthritis Rheum; 2019 Dec; 49(3):366-372. PubMed ID: 30979397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
    Lee MY; Shin JY; Park SY; Kim D; Cha HS; Lee EK
    Semin Arthritis Rheum; 2018 Feb; 47(4):485-491. PubMed ID: 28939234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
    Xie F; Yun H; Bernatsky S; Curtis JR
    Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
    Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
    Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.
    Curtis JR; Yang S; Patkar NM; Chen L; Singh JA; Cannon GW; Mikuls TR; Delzell E; Saag KG; Safford MM; DuVall S; Alexander K; Napalkov P; Winthrop KL; Burton MJ; Kamauu A; Baddley JW
    Arthritis Care Res (Hoboken); 2014 Jul; 66(7):990-7. PubMed ID: 24470378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
    Zhang J; Xie F; Yun H; Chen L; Muntner P; Levitan EB; Safford MM; Kent ST; Osterman MT; Lewis JD; Saag K; Singh JA; Curtis JR
    Ann Rheum Dis; 2016 Oct; 75(10):1813-8. PubMed ID: 26792814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
    Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
    J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study.
    Kang EH; Jin Y; Brill G; Lewey J; Patorno E; Desai RJ; Kim SC
    J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29367417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
    Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs.
    Patel V; Pulungan Z; Shah A; Kambhampati M; Lobo F; Petrilla A
    J Med Econ; 2021; 24(1):299-307. PubMed ID: 33502940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.